Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nicholas P, Giustini"'
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100419- (2022)
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory chan
Externí odkaz:
https://doaj.org/article/3a4efa3de5bb479a87cf79b15716c037
Autor:
Nicholas P, Giustini, Sandip Pravin, Patel, Nathaniel J, Myall, José, Fernando do Prado Moura, Amit, Kulkarni, Richard C, Chao, Heather, Wakelee, Lyudmila, Bazhenova
Publikováno v:
JCO precision oncology. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::085e88ab69162a10d34fc2c918f7c3fd
https://pubmed.ncbi.nlm.nih.gov/35952324
https://pubmed.ncbi.nlm.nih.gov/35952324
Publikováno v:
Lung Cancer: Targets and Therapy
Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is integral in therapy selection as its positive pred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::823fb701687b69530233b02ba2f17c29
https://doi.org/10.2147/lctt.s235102
https://doi.org/10.2147/lctt.s235102
Publikováno v:
Clinics in Chest Medicine. 41:223-235
The treatment of metastatic non-small cell lung cancer (NSCLC) is constantly evolving. Although the advent of immunotherapy has played an important role in the treatment of patients with NSCLC, the identification of driver mutations and the subsequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e26cf8f4ace53986b01cadab3230da76
https://doi.org/10.1016/j.ccm.2020.02.003
https://doi.org/10.1016/j.ccm.2020.02.003
Publikováno v:
Expert opinion on pharmacotherapy. 22(14)
Introduction: Alectinib is a second-generation inhibitor of anaplastic lymphoma kinase (ALK) and RET. Phase III clinical trials have established its superiority to crizotinib in the first-line ALK inhibitor-naive setting. Studies also support its use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061269a2394351696084ef3bb3f8e12a
https://pubmed.ncbi.nlm.nih.gov/34225542
https://pubmed.ncbi.nlm.nih.gov/34225542
Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy
Publikováno v:
Clinics in chest medicine. 41(2)
The treatment of metastatic non-small cell lung cancer (NSCLC) is constantly evolving. Although the advent of immunotherapy has played an important role in the treatment of patients with NSCLC, the identification of driver mutations and the subsequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c681de8c1456af2293ab6ae0495f6b9f
https://pubmed.ncbi.nlm.nih.gov/32402358
https://pubmed.ncbi.nlm.nih.gov/32402358
Publikováno v:
Thoracic surgery clinics. 30(2)
ROS1-rearranged non-small cell lung cancer (NSCLC) makes up approximately 1% to 2% of all NSCLC, is oncogenically driven by a constitutively activated ROS1 kinase paired with certain fusion partners, and can be detected by several different assays. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18e1f2631b1a6ebb6fffb3bf024f42f
https://pubmed.ncbi.nlm.nih.gov/32327173
https://pubmed.ncbi.nlm.nih.gov/32327173
Publikováno v:
Targeted Therapies for Lung Cancer ISBN: 9783030178314
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase, which is a member of the insulin receptor superfamily. Fusions in ALK result in constitutively activated signaling which is susceptible to inhibition by ALK tyrosine kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec6327cb7a0b93c8cdf6f51a716c387
https://doi.org/10.1007/978-3-030-17832-1_2
https://doi.org/10.1007/978-3-030-17832-1_2
Autor:
Scott F. Hickey, Steven W. Suljak, Christopher M. Rose, Michael J. Hayes, Nicholas P. Giustini, Trevor M. Axelrod, Gregory R. Stettler
Publikováno v:
The Analyst. 135:2945
The emergence of functional genomics and proteomics has added to the growing need for improved analysis methods that can detect and distinguish between protein variants resulting from allelic variation, mutation, or post-translational modification. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64f68895a4db21097dc7970814819446
https://doi.org/10.1039/c0an00445f
https://doi.org/10.1039/c0an00445f
Autor:
Christopher M. Rose, Michael J. Hayes, Gregory R. Stettler, Scott F. Hickey, Trevor M. Axelrod, Nicholas P. Giustini, Steven W. Suljak
Publikováno v:
Analyst; Nov2010, Vol. 135 Issue 11, p2945-2951, 7p